Comparison between Integris Medtech IPO and Prasol Chemicals IPO.
Integris Medtech IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Prasol Chemicals IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Integris Medtech IPO is up to ₹0.00 Cr whereas the issue size of the Prasol Chemicals IPO is up to ₹500.00 Cr. The final issue price of Integris Medtech IPO is and of Prasol Chemicals IPO is .
| Integris Medtech IPO | Prasol Chemicals IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹2 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹925.00 Cr | up to ₹80.00 Cr |
| OFS Issue Size | 2,16,74,531 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹420.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹500.00 Cr |
Integris Medtech IPO opens on , while Prasol Chemicals IPO opens on . The closing date of Integris Medtech IPO and Prasol Chemicals IPO is , and , respectively.
Integris Medtech IPO P/E ratio is , as compared to Prasol Chemicals IPO P/E ratio of .
| Integris Medtech IPO | Prasol Chemicals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Integris Medtech Ltd.'s revenue increased by 24% and profit after tax (PAT) rose by 1547% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Prasol Chemicals Ltd.'s revenue increased by 14% and profit after tax (PAT) rose by 140% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 83.24 | 47.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 5.35% | 12.57% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 14.51% | 14.95% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 1.48% | 11.86% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Integris Medtech IPO Retail Individual Investors (RII) are offered 0 shares while in Prasol Chemicals IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Integris Medtech IPO and 0 shares in Prasol Chemicals IPO.
| Integris Medtech IPO | Prasol Chemicals IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Integris Medtech IPO subscribed in total, whereas Prasol Chemicals IPO subscribed .
